EMA Application withdrawn: Movectro (cladribine) — Merck Serono Europe Limited

View source ↗

Summary

EMA withdrew the application for Movectro (cladribine) by Merck Serono Europe Limited for multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Movectro (cladribine)

Snippet

Status: Application withdrawn. Therapeutic area: Multiple Sclerosis. MAH: Merck Serono Europe Limited. Decision date: 27/09/2010